Critical overview of resection for Bismuth-Corlette type IV perihilar cholangiocarcinoma

Basit Öğe Kaydı
dc.authoridYilmaz, Sezai/0000-0002-8044-0297
dc.authoridCarr, Brian/0000-0002-6111-5077
dc.authoridKaratoprak, Sinan/0000-0003-1139-1089
dc.authorwosidYilmaz, Sezai/ABI-2323-2020
dc.contributor.authorErsan, Veysel
dc.contributor.authorUsta, Sertac
dc.contributor.authorAydin, Cemalettin
dc.contributor.authorCarr, Brian, I
dc.contributor.authorKaratoprak, Sinan
dc.contributor.authorYilmaz, Sezai
dc.date.accessioned2024-08-04T20:51:58Z
dc.date.available2024-08-04T20:51:58Z
dc.date.issued2023
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackground Current standard treatment for perihilar cholangiocarcinoma (pCCA) is surgical resection. Bismuth-Corlette (BC) type IV pCCA is accepted as an unresectable disease. In the present study, the results of non-transplant surgical approaches in patients with BC type IV pCCA were examined. Methods Medical records of consecutive patients with BC type IV pCCA between 2010 and 2021 were retrospectively reviewed. Patients were subdivided according to operation type. Postoperative survival rates were compared. Results Hemihepatectomy with caudate lobe and extrahepatic bile duct (EHBD) resection was performed in 15 patients and only EHBD resection was performed in 10 patients. Ten of the cases were found to be unresectable at the stage of laparotomy. Median follow-up was 41.3 (24.8-57.9) months. Overall survival rate for all 35 patients was 56.4% at 1 year, 32.2% at 2 years, and 16.1% at 3 years. When survivals were compared according to operation type, 1, 2, and 3-year survivals were 80%, 57.1% and 42.9% for the hepatectomy group; 55.6%, 44.4% and 11.1% for the EHBD resection group; 75%, 0% and 0% in laparotomy-only group, respectively (p = 0.13). The best survival rates were obtained in patients with pCCA who underwent hepatectomy and were lymph node negative, 100% for 1 year, 66.7 for 2 years and 50% for 3 years. Conclusion It is difficult to achieve high survival rates in BC type IV pCCA. However, these patients mostly benefit from resective treatments. Acceptable survival rates can be achieved, especially in the R0N0 patient group.en_US
dc.identifier.doi10.1080/00015458.2022.2078030
dc.identifier.endpage496en_US
dc.identifier.issn0001-5458
dc.identifier.issn2577-0160
dc.identifier.issue5en_US
dc.identifier.pmid35549649en_US
dc.identifier.scopus2-s2.0-85130917440en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage489en_US
dc.identifier.urihttps://doi.org/10.1080/00015458.2022.2078030
dc.identifier.urihttps://hdl.handle.net/11616/100677
dc.identifier.volume123en_US
dc.identifier.wosWOS:000799157700001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofActa Chirurgica Belgicaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectKlatskin tumoren_US
dc.subjectperihilar cholangiocarcinomaen_US
dc.subjectresectionen_US
dc.subjectliver transplanten_US
dc.titleCritical overview of resection for Bismuth-Corlette type IV perihilar cholangiocarcinomaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu